This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Will These 5 Drug Bigwigs Surpass Q1 Earnings Forecasts?
by Zacks Equity Research
LLY, MRK, ABBV, BMY and BIIB are set to report this week as recent beats and key drug demand set up a pivotal Q1 earnings test for pharma giants.
BIIBNegative Net Change BMYNegative Net Change MRKPositive Net Change LLYNegative Net Change ABBVNegative Net Change
biotechs pharmaceuticals
Organon Shares Rally 16% in Premarket as Sun Pharma Announces Buyout
by Zacks Equity Research
OGN stock soars as Sun Pharma strikes $11.75B all-cash deal, aiming to expand biosimilars reach and boost global pharma standing.
ANIPNegative Net Change OGNPositive Net Change INDVNo Net Change
biotechs
Will Higher Dupixent Profits, Eylea HD Sales Drive REGN's Q1 Earnings?
by Zacks Equity Research
Regeneron eyes Q1 results with Dupixent profits and strong Eylea HD uptake set to offset declining Eylea sales amid rising competition.
REGNNegative Net Change SNYPositive Net Change AZNPositive Net Change ALNYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Novo Nordisk vs. Pfizer: Which Healthcare Giant Is the Better Bet?
by Ahan Chakraborty
NVO and PFE clash as the obesity market heats up, with shifting strategies, pipeline bets and growth pressures reshaping their investment outlook.
PFENegative Net Change NVONegative Net Change LLYNegative Net Change
biotechnology biotechs medical pharmaceuticals
CRISPR Therapeutics to Report Q1 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
CRSP eyes a Q1 beat as rising Casgevy uptake, improving sales outlook and a strong Earnings ESP set the stage ahead of results.
VRTXNegative Net Change AGENNegative Net Change INONegative Net Change CRSPNegative Net Change
biotechs cell-therapy crispr earnings gene-therapy medical
Should You Buy, Hold, or Sell BMY Stock Ahead of Q1 Earnings?
by Ekta Bagri
BMY heads into Q1 earnings with strong growth portfolio momentum, but legacy drug declines and generic pressure may weigh on overall revenue performance.
BMYNegative Net Change PFENegative Net Change BNTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
by Ekta Bagri
ADMA vs. Takeda: surging Asceniv demand boosts ADMA, but Takeda's diversified portfolio and stronger returns make it the steadier pick now.
ADMANegative Net Change TAKNegative Net Change
biotechnology biotechs medical pharmaceuticals
NVO Reports Strong Phase III Diabetes Data for Children & Adolescents
by Zacks Equity Research
Novo Nordisk reports phase III teen study success for oral semaglutide, showing strong HbA1c reduction and paving the way for the first oral GLP-1 for youth.
NVONegative Net Change ANIPNegative Net Change INDVNo Net Change
biotechs
Biogen Q1 Earnings: Can New Launches Offset Declining MS Franchise?
by Zacks Equity Research
Biogen heads into Q1 earnings with new drugs like Skyclarys and Zurzuvae driving growth as legacy MS products face rising competitive pressure.
REGNNegative Net Change BIIBNegative Net Change SUPNNegative Net Change
biotechs
Incyte Gears Up to Report Q1 Earnings: What Can Investors Expect?
by Zacks Equity Research
INCY heads into Q1 earnings with a $1.23 billion revenue view, driven by Jakafi, Opzelura, rising royalties and multiple new launches contributing to revenues.
NVSNegative Net Change NVONegative Net Change LLYNegative Net Change INCYNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals